

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity CardieX Limited
ABN 81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Craig Cooper
Date of last notice	22/11/2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none">2. C2 Ventures Pty Ltd3. C2 Ventures Pty Ltd4. C2 Ventures Pty Ltd5. C2 Ventures Pty Ltd6. CooperativeHealth LLC
Date of change	12 January 2021

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct:</p> <ol style="list-style-type: none"> 1. NIL <p>Indirect:</p> <p>C2 Ventures Pty Ltd</p> <ol style="list-style-type: none"> 2. 158,960,194 FPO 3. 37,500,000 Options at \$0.05 expiring 30 November 2021 4. 221,194 Convertible Notes with face value of \$1 5. 1,500,000 Options at \$0.05 expiring 26 February 2024 <p>CooperativeHealth, LLC</p> <ol style="list-style-type: none"> 6. 36,000,000 Performance Rights
Class	See above
Number acquired	<ol style="list-style-type: none"> 1. 68,000,000 Performance Rights 2. 18,281,816 FPO 3. 4,420,455 Options 4. NIL 5. NIL 6. NIL
Number disposed	<ol style="list-style-type: none"> 1. NIL 2. NIL 3. NIL 4. 197,444 Convertible Notes 5. NIL 6. NIL
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and estimated valuation</p>	<ol style="list-style-type: none"> 1. NIL 2. \$516,250 3. NIL 4. NIL 5. NIL 6. NIL
No. of securities held after change	<p>Direct:</p> <ol style="list-style-type: none"> 1. 68,000,000 Performance Rights <p>Indirect:</p> <p>C2 Ventures Pty Ltd</p> <ol style="list-style-type: none"> 2. 177,242,010 FPO 3. 37,500,000 Options at \$0.05 expiring 30 November 2021 4. 13,750 Convertible Notes with face value of \$1 5. 1,500,000 Options at \$0.05 expiring 26 February 2024 <p>CooperativeHealth, LLC</p> <ol style="list-style-type: none"> 6. 36,000,000 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	1. Performance rights granted 2. Convertible Notes converted 3. Options granted upon shares granted in 2. 4. Convertible Notes converted 5. NIL 6. NIL
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.